应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
DVA 达维塔保健
交易中 06-12 10:05:49 EDT
207.98
+4.08
+2.00%
最高
207.98
最低
204.06
成交量
4.10万
今开
204.06
昨收
203.90
日振幅
1.92%
总市值
133.52亿
流通市值
67.86亿
总股本
6,420万
成交额
843.74万
换手率
0.13%
流通股本
3,263万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
达维塔保健新增5亿美元B-2档定期贷款额度 到期日为2031年5月
美股速递 · 06-09
达维塔保健新增5亿美元B-2档定期贷款额度 到期日为2031年5月
一周美股牛榜 | Datadog业绩大超预期，股价飙升42%；Akamai股价单周大涨42%；SMCI季度营收指引超预期，股价飙升30%；AMD涨26%；英特尔涨25%
老虎资讯综合 · 05-11
一周美股牛榜 | Datadog业绩大超预期，股价飙升42%；Akamai股价单周大涨42%；SMCI季度营收指引超预期，股价飙升30%；AMD涨26%；英特尔涨25%
异动解读 | 达维塔保健盘中大涨22.55%，一季度业绩超预期并上调全年盈利指引
异动解读 · 05-07
异动解读 | 达维塔保健盘中大涨22.55%，一季度业绩超预期并上调全年盈利指引
异动解读 | 达维塔保健盘前大涨7.10%，业绩超预期并上调全年盈利指引
异动解读 · 05-06
异动解读 | 达维塔保健盘前大涨7.10%，业绩超预期并上调全年盈利指引
异动解读 | 业绩超预期并上调盈利指引，达维塔保健夜盘大涨5.39%
异动解读 · 05-06
异动解读 | 业绩超预期并上调盈利指引，达维塔保健夜盘大涨5.39%
异动解读 | 上调年度盈利预期，达维塔保健盘后大涨5.07%
异动解读 · 05-06
异动解读 | 上调年度盈利预期，达维塔保健盘后大涨5.07%
巴菲特重仓的透析巨头，为何押注中国肾病新星？
格隆汇 · 03-18
巴菲特重仓的透析巨头，为何押注中国肾病新星？
R1 Therapeutics完成融资，Abingworth、F-Prime与达维塔风投集团联合领投，Curie.bio、Symbiosis及美国肾脏护理公司跟投
美股速递 · 03-17
R1 Therapeutics完成融资，Abingworth、F-Prime与达维塔风投集团联合领投，Curie.bio、Symbiosis及美国肾脏护理公司跟投
2025山东省十大科技创新成果发布
市场资讯 · 02-09
2025山东省十大科技创新成果发布
异动解读 | TD Cowen上调目标价，达维塔保健盘中大涨5.15%
异动解读 · 02-04
异动解读 | TD Cowen上调目标价，达维塔保健盘中大涨5.15%
异动解读 | 达维塔保健盘中大涨17.18%，年度利润预测乐观及财报超预期提振股价
异动解读 · 02-03
异动解读 | 达维塔保健盘中大涨17.18%，年度利润预测乐观及财报超预期提振股价
异动解读 | 财报及业绩指引超预期，达维塔保健盘前大涨13.54%
异动解读 · 02-03
异动解读 | 财报及业绩指引超预期，达维塔保健盘前大涨13.54%
异动解读 | 达维塔保健发布2026年业绩展望及超预期财报，夜盘大涨14.52%
异动解读 · 02-03
异动解读 | 达维塔保健发布2026年业绩展望及超预期财报，夜盘大涨14.52%
伯克希尔哈撒韦披露减持达维塔保健165.8万股 成交均价120.5561美元
美股速递 · 02-03
伯克希尔哈撒韦披露减持达维塔保健165.8万股 成交均价120.5561美元
达维塔高管预计2026年将面临约4000万美元逆风 主因交易所计划增强保费税收抵免政策到期
美股速递 · 02-03
达维塔高管预计2026年将面临约4000万美元逆风 主因交易所计划增强保费税收抵免政策到期
异动解读 | 达维塔保健发布2026年业绩展望，盘后大涨10.93%
异动解读 · 02-03
异动解读 | 达维塔保健发布2026年业绩展望，盘后大涨10.93%
达维塔保健发布2026年业绩展望：每股持续经营业务调整后净收益预计13.60至15.00美元
美股速递 · 02-03
达维塔保健发布2026年业绩展望：每股持续经营业务调整后净收益预计13.60至15.00美元
巴菲特，又有大动作！
央视财经 · 2025-02-21
巴菲特，又有大动作！
德维特2024财年实现净利润9.36亿美元，同比增加35.26%
市场透视 · 2025-02-18
德维特2024财年实现净利润9.36亿美元，同比增加35.26%
加载更多
公司概况
公司名称：
达维塔保健
所属市场：
NYSE
上市日期：
--
主营业务：
DaVita Inc.于1994年在特拉华州注册成立。达维塔保健 Inc.是一家领先的医疗保健供应商，专注于转变护理提供方式，以提高全球患者的生活质量。作为一家综合性肾脏护理提供者，达维塔保健拥有超过25年的经验，它提供的服务可在患者肾脏健康之旅的每个阶段为其提供支持——从减缓肾脏疾病的进展到促进移植。该公司经营透析中心，为家庭护理提供支持，并在医院和熟练的护理设施中提供服务。达维塔保健对创新和综合护理的承诺旨在改善结果，同时最大限度地降低成本，从而加强其作为值得信赖的提供者和合作伙伴在医疗保健领域的地位。
发行价格：
--
{"stockData":{"symbol":"DVA","market":"US","secType":"STK","nameCN":"达维塔保健","latestPrice":207.98,"timestamp":1781273146559,"preClose":203.9,"halted":0,"volume":41010,"delay":0,"changeRate":0.020009808729769415,"floatShares":32629699,"shares":64200000,"eps":10.741053,"marketStatus":"交易中","change":4.08,"latestTime":"06-12 10:05:49 EDT","open":204.0608,"high":207.98,"low":204.0608,"amount":8437406.8323,"amplitude":0.019221,"askPrice":208.17,"askSize":132,"bidPrice":207.86,"bidSize":55,"shortable":3,"etf":0,"ttmEps":10.741053,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1781294400000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":815029200000,"exchange":"NYSE","adjPreClose":203.9,"preHourTrading":{"tag":"盘前","latestPrice":205.17,"preClose":203.9,"latestTime":"09:19 EDT","volume":68,"amount":13973.764720000001,"timestamp":1781270360878,"change":1.27,"changeRate":0.006229,"amplitude":0.003384},"postHourTrading":{"tag":"盘后","latestPrice":204.4,"preClose":203.83,"latestTime":"18:49 EDT","volume":36846,"amount":7510381.5037,"timestamp":1781218183281,"change":0.57,"changeRate":0.002796,"amplitude":0.002796},"volumeRatio":0.646975,"impliedVol":0.3188,"impliedVolPercentile":0.255},"requestUrl":"/m/hq/s/DVA","defaultTab":"news","newsList":[{"id":"1119172565","title":"达维塔保健新增5亿美元B-2档定期贷款额度 到期日为2031年5月","url":"https://stock-news.laohu8.com/highlight/detail?id=1119172565","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119172565?lang=zh_cn&edition=full","pubTime":"2026-06-09 04:39","pubTimestamp":1780951151,"startTime":"0","endTime":"0","summary":"根据提交给美国证券交易委员会（SEC）的文件，达维塔保健（DaVita HealthCare Partners）为其B-2档定期贷款额度增加了5亿美元的增量借款，该贷款额度的到期日为2031年5月。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DVA","BK4196","BK4585","BK4588","BK4559"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120883918","title":"一周美股牛榜 | Datadog业绩大超预期，股价飙升42%；Akamai股价单周大涨42%；SMCI季度营收指引超预期，股价飙升30%；AMD涨26%；英特尔涨25%","url":"https://stock-news.laohu8.com/highlight/detail?id=1120883918","media":"老虎资讯综合","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120883918?lang=zh_cn&edition=full","pubTime":"2026-05-11 10:31","pubTimestamp":1778466709,"startTime":"0","endTime":"0","summary":"Datadog公布营收达10.06亿美元，同比增长32%；调整后每股收益为0.60美元，双双超越市场预期。这一消息发布之际，Akamai公布一季度每股收益为1.61美元，去年同期为1.70美元，略高于华尔街预期的1.60美元。AMD股价本周大涨26%。受此消息影响，英特尔本周涨幅扩大至25%。","market":"us","thumbnail":"https://community-static.tradeup.com/news/b709e81a1b4f7405bf5e343b3c9425a7","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/b709e81a1b4f7405bf5e343b3c9425a7"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"5a2a69dffb9a72343c1119923975b44d","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INTC","MUD","SNDK","FTNT","LINT","AMDG","SNDU","DDOG","SMCZ","DLLL","SMCC","AMDY","DVA","AMDW","INTW","SMCL","DOGD","SMCI","AMUU","MU","AMDU","SMCY","SNXX","MULL","AMDL","MUU","AMDD","AMYY","DAMD","DELL","AKAM","SMYY","AMD","SMCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183596383","title":"异动解读 | 达维塔保健盘中大涨22.55%，一季度业绩超预期并上调全年盈利指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1183596383","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183596383?lang=zh_cn&edition=full","pubTime":"2026-05-07 03:38","pubTimestamp":1778096282,"startTime":"0","endTime":"0","summary":"达维塔保健今日盘中股价大幅上涨22.55%，成为市场关注的焦点。消息面上，该公司公布了远超市场预期的2026年第一季度财务业绩，并基于肾透析服务需求的强劲与稳定增长，上调了全年调整后利润预期。具体而言，公司第一季度调整后每股收益为2.87美元，大幅高于分析师普遍预期的2.32美元；季度营收达到34.2亿美元，也超出了33.6亿美元的市场预期。同时，公司将2026年全年经调整后每股收益预期区间上调至14.10美元至15.20美元，高于此前13.60美元至15.00美元的指引。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["DVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130324878","title":"异动解读 | 达维塔保健盘前大涨7.10%，业绩超预期并上调全年盈利指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1130324878","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130324878?lang=zh_cn&edition=full","pubTime":"2026-05-06 16:40","pubTimestamp":1778056845,"startTime":"0","endTime":"0","summary":"达维塔保健（DVA）今日盘前股价大幅上涨7.10%，成为市场关注的焦点。消息面上，该公司公布了超出华尔街预期的第一季度业绩，并基于肾透析服务需求的强劲与稳定增长，上调了全年调整后利润预期。具体而言，公司目前预计2026年经调整后每股收益将在14.10美元至15.20美元之间，高于此前预测的13.60美元至15.00美元。财报数据显示，在截至3月31日的季度，该公司按调整后数据计算的每股盈利为2.87美元，高于分析师预期的2.32美元；季度营收达到34.2亿美元，也高于市场预期的33.6亿美元。这表明公司在应对患者护理和运营成本上涨的挑战后，业务已重拾增长势头，从而提振了投资者信心。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["DVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145550923","title":"异动解读 | 业绩超预期并上调盈利指引，达维塔保健夜盘大涨5.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=1145550923","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145550923?lang=zh_cn&edition=full","pubTime":"2026-05-06 11:12","pubTimestamp":1778037123,"startTime":"0","endTime":"0","summary":"达维塔保健（DVA）今日夜盘股价大涨5.39%，成为市场关注的焦点。消息面上，公司公布了超出华尔街预期的第一季度业绩，并基于肾透析服务需求的强劲与稳定增长，上调了全年调整后利润预期。具体而言，公司目前预计2026年经调整后每股收益将在14.10美元至15.20美元之间，高于此前预测的13.60美元至15.00美元。财报数据显示，在截至3月31日的季度，该公司按调整后数据计算的每股盈利为2.87美元，高于分析师预期的2.32美元；季度营收达到34.2亿美元，也高于市场预期的33.6亿美元。这表明公司在应对运营成本挑战后，业务已重拾增长势头，从而提振了投资者信心。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["DVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125490690","title":"异动解读 | 上调年度盈利预期，达维塔保健盘后大涨5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=1125490690","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125490690?lang=zh_cn&edition=full","pubTime":"2026-05-06 05:51","pubTimestamp":1778017905,"startTime":"0","endTime":"0","summary":"达维塔保健（DVA）今日盘后股价大幅上涨5.07%，成为市场关注的焦点。消息面上，该公司公布了超出华尔街预期的第一季度业绩，并基于肾透析服务需求的强劲与稳定增长，上调了全年调整后利润预期。具体而言，公司目前预计2026年经调整后每股收益将在14.10美元至15.20美元之间，高于此前预测的13.60美元至15.00美元。财报数据显示，在截至3月31日的季度，该公司按调整后数据计算的每股盈利为2.87美元，高于分析师预期的2.32美元；季度营收达到34.2亿美元，也高于市场预期的33.6亿美元。这表明公司在应对患者护理和运营成本上涨的挑战后，业务已重拾增长势头。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["DVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620407373","title":"巴菲特重仓的透析巨头，为何押注中国肾病新星？","url":"https://stock-news.laohu8.com/highlight/detail?id=2620407373","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620407373?lang=zh_cn&edition=full","pubTime":"2026-03-18 09:08","pubTimestamp":1773796126,"startTime":"0","endTime":"0","summary":"最有希望在美国“上市即放量”\n","market":"sg","thumbnail":"https://img3.gelonghui.com/02490-dd1b506f-18f3-46ab-a410-cfb69aa5569f.jpg?guru_height=853&guru_width=1280&guru_size=117711","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/02490-dd1b506f-18f3-46ab-a410-cfb69aa5569f.jpg?guru_height=853&guru_width=1280&guru_size=117711"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4100986","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["LU2487616109.SGD","IE00B775SV38.USD","LU0234572021.USD","LU1571399168.USD","IE00B1BXHZ80.USD","LU2168564495.EUR","LU0256863811.USD","IE00B3S45H60.SGD","IE00BWXC8680.SGD","LU0157215616.USD","LU0149725797.USD","LU0787776722.HKD","LU0251131958.USD","BK4176","LU1074936037.SGD","LU2168564222.USD","IE00BK4W5M84.HKD","BK4550","IE00BK4W5L77.USD","LU0648001328.SGD","IE00B1XK9C88.USD","BK4534","LU1280957306.USD","LU0980610538.SGD","BRKC","LU2168563687.JPY","BRKU","LU1914381329.SGD","IE00BKDWB100.SGD","LU0170899867.USD","DVA","HK0000914660.USD","LU0971096721.USD","LU0210528500.USD","LU0251142724.SGD","LU0640476718.USD","BK4533","LU1366333091.USD","LU2168564065.EUR","LU0683600562.USD","LU0048573561.USD","LU1201861249.SGD","IE000M9KFDE8.USD","LU2168564149.EUR","LU0053666078.USD","LU0742534661.SGD","IE00BJLML261.HKD","HK0000914686.HKD","IE0034235303.USD","LU0154236417.USD","BK4585","BK4581","BRKW","BRKD","LU0417517546.SGD","LU1363072403.SGD","BK4588","LU0130102774.USD","LU0234570918.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157539444","title":"R1 Therapeutics完成融资，Abingworth、F-Prime与达维塔风投集团联合领投，Curie.bio、Symbiosis及美国肾脏护理公司跟投","url":"https://stock-news.laohu8.com/highlight/detail?id=1157539444","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157539444?lang=zh_cn&edition=full","pubTime":"2026-03-17 19:00","pubTimestamp":1773745220,"startTime":"0","endTime":"0","summary":"生物技术公司R1 Therapeutics近日宣布成功完成新一轮融资。本轮融资由知名投资机构Abingworth、F-Prime Capital与达维塔风投集团（DaVita Venture Group）共同担任联合领投方。同时获得Curie.bio、Symbiosis以及美国肾脏护理公司（U.S. Renal Care）等多家机构的积极参与。\n此次融资将用于加速R1 Therapeutics在肾脏疾病治疗领域的创新药物研发进程，推动其前沿疗法从实验室向临床阶段转化。多方资本的注入不仅彰显了市场对肾脏病治疗赛道的信心，也为企业后续发展提供了强有力的资金保障。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4196","BK4585","BK4559","DVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610507801","title":"2025山东省十大科技创新成果发布","url":"https://stock-news.laohu8.com/highlight/detail?id=2610507801","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610507801?lang=zh_cn&edition=full","pubTime":"2026-02-09 11:07","pubTimestamp":1770606420,"startTime":"0","endTime":"0","summary":"高性能柠檬醛、高端轮胎阻隔材料上榜 中化新网讯 近日，2025年度山东省十大科技创新成果在济南发布，万华化学集团研发的高性能柠檬醛、山东道恩高分子材料股份有限公司主导研发的高端轮胎阻隔材料等成果上榜。 据了解，2025年度山东省十大科技创新成果榜单是在山东省创新发展研究院组织下，由省内外60余位院士专家从省重大科技创新成果库中严格筛选、投票产生。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-02-09/doc-inhmesxq2361974.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4585","BK4588","BK4559","BK4196","DVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192786519","title":"异动解读 | TD Cowen上调目标价，达维塔保健盘中大涨5.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=1192786519","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192786519?lang=zh_cn&edition=full","pubTime":"2026-02-04 22:46","pubTimestamp":1770216400,"startTime":"0","endTime":"0","summary":"达维塔保健今日盘中大涨5.15%，引起了市场的关注。消息面上，根据路透报道，华尔街券商TD Cowen在最新研究报告中，将达维塔保健的目标价从133美元上调至144美元。分析师上调目标价通常被视为对公司未来业绩和前景的积极信号，这增强了投资者信心并推动了股价上涨。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["DVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151712134","title":"异动解读 | 达维塔保健盘中大涨17.18%，年度利润预测乐观及财报超预期提振股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1151712134","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151712134?lang=zh_cn&edition=full","pubTime":"2026-02-03 22:47","pubTimestamp":1770130046,"startTime":"0","endTime":"0","summary":"达维塔保健今日盘中大幅上涨17.18%，引起了市场的广泛关注。消息面上，公司发布了远超市场预期的2026年年度利润预测，其给出的调整后每股收益指引区间为13.60美元至15美元，显著高于分析师平均预期的12.65美元。公司将这一乐观展望归因于对其核心肾透析服务的稳定需求。此外，公司公布的第四季度调整后每股收益为3.40美元，也超过了市场预期，利润的提升得益于报销率提高、流感疫苗组合改善以及季节性因素的积极影响。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["DVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166339596","title":"异动解读 | 财报及业绩指引超预期，达维塔保健盘前大涨13.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=1166339596","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166339596?lang=zh_cn&edition=full","pubTime":"2026-02-03 18:39","pubTimestamp":1770115172,"startTime":"0","endTime":"0","summary":"达维塔保健今日盘前股价大幅上涨13.54%，引起了市场的广泛关注。消息面上，公司公布了强劲的第四季度财报及2026年业绩展望。其第四季度调整后每股收益为3.40美元，营收为36.2亿美元，均超出市场预期。同时，公司给出的2026年调整后每股利润指引区间为13.6美元至15美元，显著高于分析师普遍预期的12.65美元。稳定的透析服务需求、较高的报销率以及运营状况的改善，共同推动了业绩向好。此外，公司宣布将与临终关怀服务提供商Elara合作，开发一种专门针对肾脏的家庭护理模式，旨在减少可预防的住院治疗并改善患者治疗效果。这一战略合作进一步增强了市场对公司未来增长潜力的信心。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["DVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186442253","title":"异动解读 | 达维塔保健发布2026年业绩展望及超预期财报，夜盘大涨14.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=1186442253","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186442253?lang=zh_cn&edition=full","pubTime":"2026-02-03 09:08","pubTimestamp":1770080936,"startTime":"0","endTime":"0","summary":"达维塔保健（DVA）今日夜盘股价大幅上涨14.52%，引起了市场的广泛关注。消息面上，公司公布了2026年度财务指引，预计调整后每股收益在13.60美元至15.00美元之间，高于分析师预期的12.65美元。同时，公司发布的第四季度财报显示，调整后每股收益为3.40美元，营收为36.2亿美元，均超出市场预期。稳定的透析服务需求、较高的报销率以及运营状况的改善，共同推动了业绩向好。此外，公司宣布将与临终关怀服务提供商Elara合作，开发针对肾脏的家庭护理模式，旨在改善患者治疗效果，这进一步增强了市场对公司未来增长潜力的信心。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["DVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184013696","title":"伯克希尔哈撒韦披露减持达维塔保健165.8万股 成交均价120.5561美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1184013696","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184013696?lang=zh_cn&edition=full","pubTime":"2026-02-03 06:36","pubTimestamp":1770071777,"startTime":"0","endTime":"0","summary":"根据最新提交的美国证券交易委员会（SEC）文件显示，伯克希尔哈撒韦公司于1月29日在公开市场出售了达维塔保健（DaVita HealthCare Partners）的普通股1,658,480股，平均成交价格为每股120.5561美元。此次交易引发了市场对伯克希尔持仓策略调整的关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","DVA","BK4585","BK4196","BK4559"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117322122","title":"达维塔高管预计2026年将面临约4000万美元逆风 主因交易所计划增强保费税收抵免政策到期","url":"https://stock-news.laohu8.com/highlight/detail?id=1117322122","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117322122?lang=zh_cn&edition=full","pubTime":"2026-02-03 06:26","pubTimestamp":1770071173,"startTime":"0","endTime":"0","summary":"达维塔保健（DaVita HealthCare Partners）高管近日透露，随着针对交易所医保计划的增强型保费税收抵免政策将于2026年到期，公司预计将面临约4000万美元的财务逆风。\n这一预测凸显了医疗保健行业对政策变动的敏感性。税收抵免政策的终止可能影响民众参与医保交易所计划的积极性，进而对达维塔等依赖相关医保计划的医疗服务提供商造成收入压力。\n公司管理层表示已开始制定应对策略，通过优化运营效率和成本结构来缓解潜在冲击。不过具体影响程度仍将取决于最终的政策走向和市场反应。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4559","DVA","BK4585","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101219967","title":"异动解读 | 达维塔保健发布2026年业绩展望，盘后大涨10.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=1101219967","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101219967?lang=zh_cn&edition=full","pubTime":"2026-02-03 05:38","pubTimestamp":1770068321,"startTime":"0","endTime":"0","summary":"达维塔保健（DVA）今日盘后股价大幅上涨10.93%，引起了市场的广泛关注。消息面上，达维塔保健公布了2026年度财务指引，预计归属于公司的持续经营业务调整后稀释每股净收益将在13.60美元至15.00美元区间。这一积极的业绩展望展现了公司对中长期盈利能力的信心，为投资者提供了明确的预期，从而提振了市场情绪，推动了股价在盘后交易时段显著走高。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["DVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198805853","title":"达维塔保健发布2026年业绩展望：每股持续经营业务调整后净收益预计13.60至15.00美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1198805853","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198805853?lang=zh_cn&edition=full","pubTime":"2026-02-03 05:11","pubTimestamp":1770066701,"startTime":"0","endTime":"0","summary":"达维塔保健（DaVita HealthCare Partners）近日公布了2026年度财务指引，预计归属于公司的持续经营业务调整后稀释每股净收益将在13.60美元至15.00美元区间。这一预测展现了公司对中长期盈利能力的信心，同时也为投资者提供了明确的业绩预期框架。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","BK4585","DVA","BK4559","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513084252","title":"巴菲特，又有大动作！","url":"https://stock-news.laohu8.com/highlight/detail?id=2513084252","media":"央视财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513084252?lang=zh_cn&edition=full","pubTime":"2025-02-21 17:13","pubTimestamp":1740129180,"startTime":"0","endTime":"0","summary":"转自：央视财经据路透社报道，近期美国证券交易委员会披露的一份文件显示，美国知名投资人巴菲特旗下伯克希尔-哈撒韦公司在2月14日至19日合计减持美国医疗保健公司达维塔（DaVita）共计75万股，套现约1.15亿美元，约合人民币8.3亿元。此次减持以后，伯克希尔持有达维塔的股份数量降至3514万股，持股比例降至43.93%。据悉，这并非巴菲特第一次减持该股，此前在2月11日也减持了约20万股。从股价表现来看，达维塔近期走势震荡，1月末一度涨至179.60美元/股，但2月14日该股突然暴跌超11%。目前达维塔最新市值为116.7亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221173826abd75f41&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221173826abd75f41&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4196","LU0053666078.USD","BRK.A","LU0742534661.SGD","LU0787776722.HKD","LU1201861249.SGD","IE00BWXC8680.SGD","IE00B1BXHZ80.USD","IE00B1XK9C88.USD","IE00BK4W5L77.USD","IE00B3S45H60.SGD","LU0234570918.USD","BK4559","LU0640476718.USD","LU0234572021.USD","LU1280957306.USD","BK4176","LU1571399168.USD","BK4550","LU1914381329.SGD","BK4581","IE000M9KFDE8.USD","LU0683600562.USD","LU0417517546.SGD","LU1074936037.SGD","BRK.B","IE00B775SV38.USD","LU0170899867.USD","DVA","LU1366333091.USD","LU1363072403.SGD","LU0256863811.USD","LU0149725797.USD","LU0648001328.SGD","IE0034235303.USD","LU0130102774.USD","LU0251131958.USD","BK4533","IE00BKDWB100.SGD","LU0048573561.USD","LU0971096721.USD","LU0980610538.SGD","BK4588","BK4585","LU0154236417.USD","IE00BK4W5M84.HKD","LU0251142724.SGD","LU0157215616.USD","BK4534"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512267829","title":"德维特2024财年实现净利润9.36亿美元，同比增加35.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512267829","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512267829?lang=zh_cn&edition=full","pubTime":"2025-02-18 00:00","pubTimestamp":1739808034,"startTime":"0","endTime":"0","summary":"2月18日，德维特公布财报，公告显示公司2024财年净利润为9.36亿美元，同比增加35.26%；其中营业收入为128.16亿美元，同比增加5.57%，每股基本收益为11.02美元。从资产负债表来看，德维特总负债158.81亿美元，其中短期债务6.81亿美元，资产负债比为1.14，流动比率为1.27。机构评级：截至2025年2月18日，当前有7家机构对德维特目标价做出预测，其中目标均价为167.00美元，其中最低目标价为145.00美元，最高目标价为186.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218000043a2496358&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218000043a2496358&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["DVA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.davita.com","stockEarnings":[{"period":"1week","weight":0.0607},{"period":"1month","weight":0.0164},{"period":"3month","weight":0.3524},{"period":"6month","weight":0.6797},{"period":"1year","weight":0.4752},{"period":"ytd","weight":0.7941}],"compareEarnings":[{"period":"1week","weight":-0.0255},{"period":"1month","weight":-0.0006},{"period":"3month","weight":0.114},{"period":"6month","weight":0.0821},{"period":"1year","weight":0.2268},{"period":"ytd","weight":0.0819}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"DaVita Inc.于1994年在特拉华州注册成立。达维塔保健 Inc.是一家领先的医疗保健供应商，专注于转变护理提供方式，以提高全球患者的生活质量。作为一家综合性肾脏护理提供者，达维塔保健拥有超过25年的经验，它提供的服务可在患者肾脏健康之旅的每个阶段为其提供支持——从减缓肾脏疾病的进展到促进移植。该公司经营透析中心，为家庭护理提供支持，并在医院和熟练的护理设施中提供服务。达维塔保健对创新和综合护理的承诺旨在改善结果，同时最大限度地降低成本，从而加强其作为值得信赖的提供者和合作伙伴在医疗保健领域的地位。","yearOnYearQuotes":[{"month":1,"riseRate":0.516129,"avgChangeRate":0.002865},{"month":2,"riseRate":0.483871,"avgChangeRate":-0.007883},{"month":3,"riseRate":0.548387,"avgChangeRate":0.019696},{"month":4,"riseRate":0.645161,"avgChangeRate":0.025606},{"month":5,"riseRate":0.612903,"avgChangeRate":0.026568},{"month":6,"riseRate":0.612903,"avgChangeRate":0.045444},{"month":7,"riseRate":0.533333,"avgChangeRate":-0.007824},{"month":8,"riseRate":0.433333,"avgChangeRate":-0.005884},{"month":9,"riseRate":0.566667,"avgChangeRate":0.017103},{"month":10,"riseRate":0.5,"avgChangeRate":0.001552},{"month":11,"riseRate":0.612903,"avgChangeRate":0.050929},{"month":12,"riseRate":0.580645,"avgChangeRate":0.040515}],"exchange":"NYSE","name":"达维塔保健","nameEN":"DaVita HealthCare Partners"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"达维塔保健(DVA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供达维塔保健(DVA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"达维塔保健,DVA,达维塔保健股票,达维塔保健股票老虎,达维塔保健股票老虎国际,达维塔保健行情,达维塔保健股票行情,达维塔保健股价,达维塔保健股市,达维塔保健股票价格,达维塔保健股票交易,达维塔保健股票购买,达维塔保健股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"达维塔保健(DVA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供达维塔保健(DVA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}